<DOC>
	<DOCNO>NCT01147289</DOCNO>
	<brief_summary>A phase III , randomize , multicenter , open label clinical trial evaluate efficacy safety injectable association dexamethasone , dipyrone , hydroxocobalamin lumbar sciatic pain . The study enroll 140 patient arm ( 280 total ) .</brief_summary>
	<brief_title>Efficacy Safety Injectable Association Dexamethasone , Dipyrone Hydrocobalamin Lumbar Sciatic Pain</brief_title>
	<detailed_description />
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dipyrone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<criteria>Sign study inform consent form ; To diagnose moderate severe lumbar sciatic pain ( define limit work activity ordinary task performance investigator 's discretion ) within last 3 day ; Aged 18 75 year old ; To able meet study procedure oDiagnosed chronic rheumatologic disease , except recurrent lumbar sciatic pain ; Patients one follow condition , per investigator 's criterion : Severe renal failure hemodialysis , severe liver failure , uncontrolled severe heart failure ; Severe injuries gastrointestinal tract ; Other severe comorbidities ; Patients take acetylsalicylic acid anticlotting ; Female patient pregnant , lactating , willing get pregnant willing use appropriate contraceptive method study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>lumbar sciatic pain</keyword>
	<keyword>moderate severe lumbar sciatic pain within last three day</keyword>
</DOC>